Board of Directors

Earl Collier, Jr.
Executive VP, Genzyme

Earl Collier is executive vice president of Genzyme Corporation. He is responsible for managing Genzyme’s oncology and cardiovascular businesses. He joined Genzyme full time in 1997, but his relationship with the company dates to 1990, when he began working with Genzyme as an outside lawyer. At Genzyme he was also president of Genzyme Biosurgery and its predecessor, Genzyme Surgical Products.

Mr. Collier has more than 20 years of experience in healthcare. He was president of Vitas Healthcare Corp from 1991 to 1995. Vitas is the largest provider of hospice services in the U.S. Between 1981 and 1991, Mr. Collier was a partner at Hogan & Hartson law firm in Washington, D.C. He served as deputy administrator for the Health Care Financing Administration (HCFA) in Baltimore, MD, during the Carter Administration. From 1977 to 1979, Mr. Collier was deputy administrator of the New York State offices of Health Systems Management. Mr. Collier was an associate at Covington and Burlington law firm in Washington, D.C., from 1974 to 1977. He began his legal career in Washington as a clerk for the U.S. Court of Appeals.

Mr. Collier sits on the board of The Covalent Group, Inc. and Excigen Inc. He earned a B.A. at Yale University and a J.D. at the University of Virginia Law School.

Gary Ellis
Sr. Vice President & Chief Financial Officer, Medtronic

Gary Ellis was named Sr. Vice President and Chief Financial Officer effective May 1, 2005. He is responsible for the following functions: treasury, tax controllership, internal audit, investor relations, and corporate development. Shortly after being named CFO, Gary was made responsible for Global Business Solutions (which includes quality, supply chain, facilities, and all facets of information systems) at Medtronic. In October 1999, Ellis was named Vice President, Corporate Controller and Treasurer, adding the Corporate Treasury functions to his area of responsibility. Ellis was named Vice President and Corporate Controller in August 1994, with responsibility for the finance and accounting functions throughout Medtronic. Ellis had been promoted to Vice President of Finance for Medtronic Europe in 1992 after joining Medtronic in 1989 as Assistant Corporate Controller.

Before coming to Medtronic, Ellis was a Senior Audit Manager for Price Waterhouse where, in addition to several other responsibilities, he managed the Medtronic audit for nearly ten years. He has worked with several large corporate organizations, as well as providing audit services to numerous non-profit organizations.

Ellis received his Bachelor of Science in Accounting in 1978 from the University of South Dakota. Gary is very active in community activities and has contributed many years of service on the Board of Directors and as President of his local church and other non-profit organizations. He serves on the Board of Directors of the American Heart Association at the national level and is currently a member of the Minnesota Society of CPAs.

Ellis currently resides in Woodbury, Minnesota, with his wife, Sue. They have two children.

James Geraghty
Senior VP, Genzyme

James Geraghty is Senior Vice President and an Officer of Genzyme Corporation. He was President of Genzyme Europe from 1998-2002, led Genzyme’s acquisition of Sangstat Medical Corporation in 2003, and in 2004 became General Manager of Genzyme’s cardiovascular business. Mr. Geraghty serves as a Director of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), where he was Chairman from 1998 to 2001, and President and C.E.O. from its founding in 1993. He also serves as a member of the boards of Therapeutic Human Polyclonals, Inc., Excigen Inc., and Myosix SA, and of the Advisory Board of the KBC Biotech Fund.

Richard Gregory
Senior VP and Head of Research, Genzyme

Rich received his Ph.D. in Biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology in Shrewsbury MA. In 1989 he joined Genzyme Corporation, where he was responsible for a number of discovery projects in the molecular biology department. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation of CFTR. Richard received the Genzyme President’s award for this work in 1991. This research on the molecular basis of cystic fibrosis led to the development of Genzyme’s CF gene therapy program, for which Richard was Project Team Leader until 1993. From 1993 to 1995 he was Director of Molecular Biology at Canji, Inc. in San Diego, where he conducted research on development of gene therapies for cancer. Dr. Gregory returned to Genzyme in 1995 to head the gene therapy program as Vice President for Gene Therapy. Research efforts under Dr. Gregory’s direction during this period included programs in cancer immunotherapy, gene therapies for genetic diseases and cardiovascular gene therapy. In 2003, Richard was appointed Head of Research for Genzyme Corporation and currently is responsible for oversight of pre-clinical research conducted at Genzyme. He is the co-author of over 60 peer-reviewed publications and 17 issued U.S. patents in the area of biotechnology.

William Hawkins
President and COO, Medtronic

William Hawkins was elected President and Chief Operating Officer of Medtronic, Inc., effective May 3, 2004. Previously, he served as Senior Vice President and President of Medtronic’s Vascular business.

Mr. Hawkins joined Medtronic in January 2002 from Novoste Corp., where he had been President and Chief Executive Officer since 1998. Earlier positions included Corporate Vice President and President of the Sherwood Davis and Geck organization of American Home Products; President of the Ethicon Endo-Surgery organization of Johnson & Johnson; President, Devices for Vascular Intervention and U.S. Operations, for Guidant Corp.; and several increasingly responsible executive positions culminating in the presidency of the Ivac organization for Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.

Mr. Hawkins received his Bachelor of Science degree in electrical and biomedical engineering from Duke University in 1976 and received a Master of Business Administration Degree from the Darden School of Business, University of Virginia, in 1982. Mr. Hawkins is a member of the Board of Visitors of the Engineering School of Duke University, the Board of Deluxe and the Guthrie Theatre Board.

Stephen Oesterle, M.D.
Senior VP for Medicine and Technology, Medtronic

Dr. Stephen Oesterle joined Medtronic in January 2002, after serving as Associate Professor of Medicine at the Harvard University Medical School and Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. In his position as Senior Vice President for Medicine and Technology, Dr. Oesterle provides executive leadership for Medtronic scientific research, formation of technological strategies and continued development of strong cooperative relationships with the world’s medical communities.

Version 1.2

Terms and Conditions of Use | Privacy Policy | © 2004-2008 MG Biotherapeutics. All rights reserved.